Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT for actinic keratosis in Chinese adults
ChiCTR2000032656Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoints: Clinical and dermoscopic complete remission rate at 1 month after the last treatment and Clinical and dermoscopic partial response rate at 1 month after the last treatment. Started Apr 2020; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on ChiCTR2000032656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032656.